Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$43 Mln
P/E Ratio
--
P/B Ratio
0.32
Industry P/E
--
Debt to Equity
0.05
ROE
-0.55 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-13.68
CFO
$-288.42 Mln
EBITDA
$-347.67 Mln
Net Profit
$-331.66 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Kezar Life Sciences (KZR)
| -16.96 | -11.43 | -14.42 | -35.92 | -67.04 | -30.70 | -- |
|
BSE Sensex
| -2.43 | 0.54 | -3.62 | 6.02 | 9.68 | 21.97 | 10.37 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|---|
|
Kezar Life Sciences (KZR)
| -29.06 | -86.51 | -57.89 | 220.31 | 30.17 | -83.01 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.18 | 10,372.39 | 21.06 | 23.13 | |
| 32.45 | 12,882.28 | -- | -28.77 | |
| 110.07 | 10,998.29 | 33.53 | 14.16 | |
| 73.45 | 7,759.66 | 34.18 | 19.71 |
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead... product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Address: 4000 Shoreline Court, South San Francisco, CA, United States, 94080 Read more
Co-Founder, CEO & Director
Dr. Christopher J. Kirk Ph.D.
Co-Founder, CEO & Director
Dr. Christopher J. Kirk Ph.D.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Kezar Life Sciences Inc (KZR) stood at $ 185 Mln as on 30-Sep-24
The share price of Kezar Life Sciences Inc (KZR) is $5.58 (NASDAQ) as of 20-Mar-2025 16:00 EDT. Kezar Life Sciences Inc (KZR) has given a return of -67.04% in the last 3 years.
Kezar Life Sciences Inc (KZR) has a market capitalisation of $ 43 Mln as on 20-Mar-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Kezar Life Sciences Inc (KZR) is 0.32 times as on 20-Mar-2025, a 88% discount to its peers’ median range of 2.71 times.
Since, TTM earnings of Kezar Life Sciences Inc (KZR) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Kezar Life Sciences Inc (KZR) and enter the required number of quantities and click on buy to purchase the shares of Kezar Life Sciences Inc (KZR).
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Address: 4000 Shoreline Court, South San Francisco, CA, United States, 94080
The CEO & director of Dr. Christopher J. Kirk Ph.D.. is Kezar Life Sciences Inc (KZR), and CFO & Sr. VP is Dr. Christopher J. Kirk Ph.D..
There is no promoter pledging in Kezar Life Sciences Inc (KZR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,168
|
|
|
1,141
|
|
|
1,072
|
|
|
1,045
|
| Kezar Life Sciences Inc. (KZR) | Ratios |
|---|---|
|
Return on equity(%)
|
-63.18
|
|
Operating margin(%)
|
1734.99
|
|
Net Margin(%)
|
1764.52
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Kezar Life Sciences Inc (KZR) was $0 Mln.
$-0.25
(
